Patents by Inventor RALPH SCULLY

RALPH SCULLY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of CDK Inhibitors to Enhance Growth and Self-Renewal of Progenitor Cells
    Publication number: 20230365931
    Abstract: Methods for using cyclin-dependent kinase (CDK) inhibitors to enhance growth and self-renewal of progenitor cells, in vitro and in vivo.
    Type: Application
    Filed: April 24, 2023
    Publication date: November 16, 2023
    Inventors: MERAV SOCOLOVSKY, Ralph Scully, Yung Hwang
  • Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
    Patent number: 11661581
    Abstract: Methods for using cyclin-dependent kinase (CDK) inhibitors to enhance growth and self-renewal of progenitor cells, in vitro and in vivo.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: May 30, 2023
    Assignee: University of Massachusetts
    Inventors: Merav Socolovsky, Ralph Scully, Yung Hwang
  • Compositions and methods for characterizing a DNA repair variant polypeptide
    Patent number: 10697026
    Abstract: As described below, the present invention provides quantitative homologous recombination assays developed to characterize the pathogenicity DNA repair polypeptides (e.g., BRCA1, BRCA2, Rad51) and provide urgently needed functional information on the significance of DNA repair variants of uncertain significance (VUS) alleles. The invention also provides a method of generating site-specific recombination at a genomic locus or site-specific genome editing by inhibiting replication at the genomic locus, e.g., involving contacting the genomic locus with polypeptides that specifically bind target sequences at the genomic locus.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: June 30, 2020
    Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Ralph Scully, Nicholas A. Willis
  • COMPOSITIONS AND METHODS FOR CHARACTERIZING A DNA REPAIR VARIANT POLYPEPTIDE
    Publication number: 20190002990
    Abstract: As described below, the present invention provides quantitative homologous recombination assays developed to characterize the pathogenicity DNA repair polypeptides (e.g., BRCA1, BRCA2, Rad51) and provide urgently needed functional information on the significance of DNA repair variants of uncertain significance (VUS) alleles. The invention also provides a method of generating site-specific recombination at a genomic locus or site-specific genome editing by inhibiting replication at the genomic locus, e.g., involving contacting the genomic locus with polypeptides that specifically bind target sequences at the genomic locus.
    Type: Application
    Filed: July 6, 2018
    Publication date: January 3, 2019
    Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Ralph Scully, Nicholas A. Willis
  • Use of CDK Inhibitors to Enhance Growth and Self-Renewal of Progenitor Cells
    Publication number: 20180340148
    Abstract: Methods for using cyclin-dependent kinase (CDK) inhibitors to enhance growth and self-renewal of progenitor cells, in vitro and in vivo.
    Type: Application
    Filed: May 24, 2018
    Publication date: November 29, 2018
    Inventors: Merav Socolovsky, Ralph Scully, Yung Hwang
  • Compositions and methods for characterizing a DNA repair variant polypeptide
    Patent number: 10017825
    Abstract: As described below, the present invention provides quantitative homologous recombination assays developed to characterize the pathogenicity DNA repair polypeptides (e.g., BRCA1, BRCA2, Rad51) and provide urgently needed functional information on the significance of DNA repair variants of uncertain significance (VUS) alleles. The invention also provides a method of generating site-specific recombination at a genomic locus or site-specific genome editing by inhibiting replication at the genomic locus, e.g., involving contacting the genomic locus with polypeptides that specifically bind target sequences at the genomic locus.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: July 10, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Ralph Scully, Nicholas A. Willis
  • COMPOSITIONS AND METHODS FOR CHARACTERIZING A DNA REPAIR VARIANT POLYPEPTIDE
    Publication number: 20160160291
    Abstract: As described below, the present invention provides quantitative homologous recombination assays developed to characterize the pathogenicity DNA repair polypeptides (e.g., BRCA1, BRCA2, Rad51) and provide urgently needed functional information on the significance of DNA repair variants of uncertain significance (VUS) alleles. The invention also provides a method of generating site-specific recombination at a genomic locus or site-specific genome editing by inhibiting replication at the genomic locus, e.g., involving contacting the genomic locus with polypeptides that specifically bind target sequences at the genomic locus.
    Type: Application
    Filed: November 16, 2015
    Publication date: June 9, 2016
    Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: RALPH SCULLY, NICHOLAS A. WILLIS